SUNDAY QUESTION: Which of the following is the most appropriate initial management option?
#eLearning #MedEdu
#eLearning #MedEdu
January 18, 2026 at 4:00 PM
SUNDAY QUESTION: Which of the following is the most appropriate initial management option?
#eLearning #MedEdu
#eLearning #MedEdu
MAP, terlipressin & HRS-AKI: why pressure matters. Terlipressin raises MAP via splanchnic vasoconstriction, improving renal perfusion. Higher MAP is linked to HRS-AKI reversal. Target MAP during therapy.
January 10, 2026 at 6:06 AM
MAP, terlipressin & HRS-AKI: why pressure matters. Terlipressin raises MAP via splanchnic vasoconstriction, improving renal perfusion. Higher MAP is linked to HRS-AKI reversal. Target MAP during therapy.
ICYMI: Pharmacokinetics of terlipressin after single I.v. doses to healthy volunteers
Pharmacokinetics of terlipressin after single I.v. doses to healthy volunteers
The pharmacokinetics of triglycyl-lysine-vasopressin (TGLVP) were studied in healthy male volunteers after single i.v. injections of 5, 10 and 20 micrograms/kg b. wt. The half-life of distribution and elimination was 8 and 50 min, respectiv...
eurekamag.com
January 8, 2026 at 5:43 AM
ICYMI: Pharmacokinetics of terlipressin after single I.v. doses to healthy volunteers
Pharmacokinetics of terlipressin after single I.v. doses to healthy volunteers
Pharmacokinetics of terlipressin after single I.v. doses to healthy volunteers
The pharmacokinetics of triglycyl-lysine-vasopressin (TGLVP) were studied in healthy male volunteers after single i.v. injections of 5, 10 and 20 micrograms/kg b. wt. The half-life of distribution and elimination was 8 and 50 min, respectiv...
eurekamag.com
January 7, 2026 at 5:42 AM
Pharmacokinetics of terlipressin after single I.v. doses to healthy volunteers
it’s pretty wild that they managed to get IRBs to approve an RCT of terlipressin vs placebo (CONFIRM trial)
yeah of course it worked, probably dopamine would be better than placebo 🤷♂️
yeah of course it worked, probably dopamine would be better than placebo 🤷♂️
November 23, 2025 at 2:40 AM
it’s pretty wild that they managed to get IRBs to approve an RCT of terlipressin vs placebo (CONFIRM trial)
yeah of course it worked, probably dopamine would be better than placebo 🤷♂️
yeah of course it worked, probably dopamine would be better than placebo 🤷♂️
Yes, they are super into terlipressin.
As an ICU person, I must admit I don't see the attraction to terli.
(Full disclosure: my center doesn't have terlipressin, regardless, but for any ICU patient, norepinephrine seems easier to use, equally as effective, and lower risk of pulmonary edema)
As an ICU person, I must admit I don't see the attraction to terli.
(Full disclosure: my center doesn't have terlipressin, regardless, but for any ICU patient, norepinephrine seems easier to use, equally as effective, and lower risk of pulmonary edema)
November 23, 2025 at 12:52 AM
Yes, they are super into terlipressin.
As an ICU person, I must admit I don't see the attraction to terli.
(Full disclosure: my center doesn't have terlipressin, regardless, but for any ICU patient, norepinephrine seems easier to use, equally as effective, and lower risk of pulmonary edema)
As an ICU person, I must admit I don't see the attraction to terli.
(Full disclosure: my center doesn't have terlipressin, regardless, but for any ICU patient, norepinephrine seems easier to use, equally as effective, and lower risk of pulmonary edema)
Is it the ADQI one which loves terlipressin?
November 22, 2025 at 9:46 PM
Is it the ADQI one which loves terlipressin?
I don’t have experience using it, but terlipressin was approved by the FDA in September 2022 for treatment of HRS in adults with rapid reduction in kidney function and has been on our formulary for a couple years now.
November 19, 2025 at 7:40 PM
I don’t have experience using it, but terlipressin was approved by the FDA in September 2022 for treatment of HRS in adults with rapid reduction in kidney function and has been on our formulary for a couple years now.
The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review | BMC Anesthesiology
https://www.europesays.com/ie/167982/
Yang J, Endo Y, Munir MM, Woldesenbet S, Altaf A, Limkemann A, et al. Waitlist time, age, and…
https://www.europesays.com/ie/167982/
Yang J, Endo Y, Munir MM, Woldesenbet S, Altaf A, Limkemann A, et al. Waitlist time, age, and…
The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review | BMC Anesthesiology - Ireland
Yang J, Endo Y, Munir MM, Woldesenbet S, Altaf A, Limkemann A, et al. Waitlist time, age, and social vulnerability: impact on the survival benefit of deceased
www.europesays.com
November 7, 2025 at 2:00 PM
The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review | BMC Anesthesiology
https://www.europesays.com/ie/167982/
Yang J, Endo Y, Munir MM, Woldesenbet S, Altaf A, Limkemann A, et al. Waitlist time, age, and…
https://www.europesays.com/ie/167982/
Yang J, Endo Y, Munir MM, Woldesenbet S, Altaf A, Limkemann A, et al. Waitlist time, age, and…
some hospitals have terlipressin in USA but not here
agree 💯💯
agree 💯💯
November 6, 2025 at 9:57 PM
some hospitals have terlipressin in USA but not here
agree 💯💯
agree 💯💯
AKI in cirrhosis: check volume early. Albumin x48h → ~40% response; 2 pts had pulmonary edema. If HRS → terlipressin+albumin 61% response; if not HRS → targeted AKI therapy 70%. 19% needed RRT; etiologies: ATN 57%, hypovolemia 25%. #AKI #Cirrhosis #HRS #KidneyWk
November 6, 2025 at 8:17 PM
AKI in cirrhosis: check volume early. Albumin x48h → ~40% response; 2 pts had pulmonary edema. If HRS → terlipressin+albumin 61% response; if not HRS → targeted AKI therapy 70%. 19% needed RRT; etiologies: ATN 57%, hypovolemia 25%. #AKI #Cirrhosis #HRS #KidneyWk
Do you have access to Terlipressin in the US? We use it quite a lot, 4 hourly dosing so can usually be given on the ward and sometimes keeps them out of the ICU (when not in MOF..)
November 6, 2025 at 6:52 PM
Do you have access to Terlipressin in the US? We use it quite a lot, 4 hourly dosing so can usually be given on the ward and sometimes keeps them out of the ICU (when not in MOF..)
HRS-AKI vasoconstrictors:
Midodrine 5–15 mg TID + Octreotide 100–200 mcg SQ TID: floor-friendly, cheap, but ~10–15%.
Vasopressin 0.01–0.04 U/min or Terlipressin 1–2 mg IV q4–6h: ~50%; watch ischemia/resp.
Norepi: effective, needs ICU. #KidneyWk
Midodrine 5–15 mg TID + Octreotide 100–200 mcg SQ TID: floor-friendly, cheap, but ~10–15%.
Vasopressin 0.01–0.04 U/min or Terlipressin 1–2 mg IV q4–6h: ~50%; watch ischemia/resp.
Norepi: effective, needs ICU. #KidneyWk
November 6, 2025 at 5:43 PM
HRS-AKI vasoconstrictors:
Midodrine 5–15 mg TID + Octreotide 100–200 mcg SQ TID: floor-friendly, cheap, but ~10–15%.
Vasopressin 0.01–0.04 U/min or Terlipressin 1–2 mg IV q4–6h: ~50%; watch ischemia/resp.
Norepi: effective, needs ICU. #KidneyWk
Midodrine 5–15 mg TID + Octreotide 100–200 mcg SQ TID: floor-friendly, cheap, but ~10–15%.
Vasopressin 0.01–0.04 U/min or Terlipressin 1–2 mg IV q4–6h: ~50%; watch ischemia/resp.
Norepi: effective, needs ICU. #KidneyWk
Mallinckrodt to Showcase Innovative Terlipressin Findings at the 2025 AASLD Annual Meeting#United_States#Washington_D.C.#Mallinckrodt#Hepatorenal_Syndrome#Terlipressin
Mallinckrodt to Showcase Innovative Terlipressin Findings at the 2025 AASLD Annual Meeting
Mallinckrodt plc will present groundbreaking results on Terlipressin for hepatorenal syndrome during the upcoming AASLD 2025 meeting in Washington, D.C.
third-news.com
October 31, 2025 at 12:16 PM
Mallinckrodt to Showcase Innovative Terlipressin Findings at the 2025 AASLD Annual Meeting#United_States#Washington_D.C.#Mallinckrodt#Hepatorenal_Syndrome#Terlipressin
Mallinckrodt to Showcase Terlipressin Research at Kidney Week 2025#United_States#Houston#Mallinckrodt#CKD#Terlipressin
Mallinckrodt to Showcase Terlipressin Research at Kidney Week 2025
Mallinckrodt will present critical data on terlipressin during Kidney Week 2025, highlighting its effects on patients with hepatorenal syndrome-acute kidney injury.
third-news.com
October 30, 2025 at 12:24 PM
Mallinckrodt to Showcase Terlipressin Research at Kidney Week 2025#United_States#Houston#Mallinckrodt#CKD#Terlipressin
2/ Vasoconstrictors:
1️⃣ Terlipressin
- CONFIRM trial
- Contraindications: Cr > 5, MELD > 35, ACLF grade 3, volume overload, or active ischemia
2️⃣ Norepinephrine
3️⃣ Midodrine, octreotide
- Usually only given if contraindications to terlipressin
1️⃣ Terlipressin
- CONFIRM trial
- Contraindications: Cr > 5, MELD > 35, ACLF grade 3, volume overload, or active ischemia
2️⃣ Norepinephrine
3️⃣ Midodrine, octreotide
- Usually only given if contraindications to terlipressin
October 22, 2025 at 11:02 AM
2/ Vasoconstrictors:
1️⃣ Terlipressin
- CONFIRM trial
- Contraindications: Cr > 5, MELD > 35, ACLF grade 3, volume overload, or active ischemia
2️⃣ Norepinephrine
3️⃣ Midodrine, octreotide
- Usually only given if contraindications to terlipressin
1️⃣ Terlipressin
- CONFIRM trial
- Contraindications: Cr > 5, MELD > 35, ACLF grade 3, volume overload, or active ischemia
2️⃣ Norepinephrine
3️⃣ Midodrine, octreotide
- Usually only given if contraindications to terlipressin
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome www.sciencedirect.com/science/arti... #hvhebron #hepato [Text complet]
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome
Terlipressin is indicated to treat hepatorenal syndrome (HRS)-acute kidney injury (AKI), but is likely used outside this primary indication in clinica…
www.sciencedirect.com
September 18, 2025 at 8:43 AM
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome www.sciencedirect.com/science/arti... #hvhebron #hepato [Text complet]
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome
#nephsky
www.sciencedirect.com/science/arti...
#nephsky
www.sciencedirect.com/science/arti...
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome
Terlipressin is indicated to treat hepatorenal syndrome (HRS)-acute kidney injury (AKI), but is likely used outside this primary indication in clinica…
www.sciencedirect.com
September 13, 2025 at 3:26 AM
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome
#nephsky
www.sciencedirect.com/science/arti...
#nephsky
www.sciencedirect.com/science/arti...
Would terlipressin not be an alternative for the liver fx group?
September 11, 2025 at 4:17 PM
Would terlipressin not be an alternative for the liver fx group?